Identification of the biomarker IL-23 in Glioblastoma multiforme cell line T98G using ELISA
Session Number
Project ID: MEDH 28
Advisor(s)
Dr. Sowmya Anjur, Illinois Mathematics and Science Academy
Discipline
Medical and Health Sciences
Start Date
20-4-2022 9:30 AM
End Date
20-4-2022 9:45 AM
Abstract
The prognosis for patients with Glioblastoma multiforme is about 6% within 5 years of diagnosis. However, if caught earlier, the astrocytes that form glioblastoma can be detected in order to treat and prevent the spread of the cancer. This makes the use of biomarkers useful for diagnosis and tracking the progression of Glioblastoma multiforme. ELISA tests were done to test Glioblastoma cell line T98G cell cultures for the IL-23 antigen, to identify its effectiveness as a biomarker. The concentration of IL-23 in the cells was read at 450 nm with a plate reader and quantified using known standards. Current testing indicates that the IL-23 biomarker will either be present in low amounts or be absent in the tissue samples studied.
Identification of the biomarker IL-23 in Glioblastoma multiforme cell line T98G using ELISA
The prognosis for patients with Glioblastoma multiforme is about 6% within 5 years of diagnosis. However, if caught earlier, the astrocytes that form glioblastoma can be detected in order to treat and prevent the spread of the cancer. This makes the use of biomarkers useful for diagnosis and tracking the progression of Glioblastoma multiforme. ELISA tests were done to test Glioblastoma cell line T98G cell cultures for the IL-23 antigen, to identify its effectiveness as a biomarker. The concentration of IL-23 in the cells was read at 450 nm with a plate reader and quantified using known standards. Current testing indicates that the IL-23 biomarker will either be present in low amounts or be absent in the tissue samples studied.